跳至主要内容
临床试验/EUCTR2010-019791-73-NL
EUCTR2010-019791-73-NL进行中(未招募)1 期

A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)

Sanofi-aventis recherche & développement0 个研究点目标入组 10,800 人开始时间: 2010年6月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
10,800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Permanent AF defined by the presence of all of the following criteria:
  • - Availability of one 12-lead ECG not more than 14 days prior to randomization showing that the patient is in AF or atrial flutter
  • - Availability of documentation (including either rhythm strips or medical report of the rhythm) showing that the patient was in AF or atrial flutter at least 6 months prior to randomization
  • - No evidence of sinus rhythm in the period between these two documentations of AF
  • - Patient and physician decision to allow AF to continue without further efforts to restore sinus rhythm
  • Patients aged 65 years or older with at least one of the following risk criteria:
  • - Coronary artery disease
  • - Prior stroke or Transient Ischemic Attack (TIA)
  • - Symptomatic heart failure
  • - Left ventricular ejection fraction less or equal to 0.40
  • - Peripheral arterial occlusive disease
  • - Aged 75 years or older with both hypertension and diabetes mellitus
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Paroxysmal AF
  • - Persistent AF without a decision to allow AF to continue without further efforts to restore sinus rhythm
  • - Heart failure of New-York Heart Association (NYHA) class IV or recent unstable NYHA class III

研究者

相似试验

进行中(未招募)
1 期
Investigate the safety and efficacy of study drug ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have failed to other treatments.Moderate to Severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856
EUCTR2018-003558-26-DEABIVAX232
招募中
不适用
Effect of herbal extract on reducing body fat in healthy adults
CTRI/2022/10/046429Sangol Farm
进行中(未招募)
不适用
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)MedDRA version: 13.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial Fibrillation
EUCTR2010-019791-73-DKSanofi-aventis recherche & développement10,800
进行中(未招募)
不适用
A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infectioHigh grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infectionMedDRA version: 9.1Level: LLTClassification code 10049701Term: Cervical intraepithelial neoplasia IIMedDRA version: 9.1Level: LLTClassification code 10049702Term: Cervical intraepithelial neoplasia III
EUCTR2008-006946-24-DEF. Hoffmann-La Roche Ltd200
尚未招募
不适用
A clinical study to establish the safety and efficacy of a natural formulation -Asdamarin in dyspepsia patients
CTRI/2018/05/013993Vidya Herbs Private Limited
A randomized, double blind, placebo controlled,... | 临床试验